Difference between revisions of "Sapacitabine (CS-682)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
||
| Line 8: | Line 8: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Oral | + | [[Category:Oral medications]] |
[[Category:Pyrimidine analogues]] | [[Category:Pyrimidine analogues]] | ||
Revision as of 17:10, 25 July 2017
Mechanism of action
Pyrimidine analogue
Preliminary results
Acute myeloid leukemia
- Hagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, Selina Luger, Parameswaran Venugopal, Lori Maness, Meir Wetzler, Steven Coutre, Wendy Stock, David Claxton, Stuart L Goldberg, Martha Arellano, Stephen A Strickland, Karen Seiter, Gary Schiller, Elias Jabbour, Judy Chiao, William Plunkett, Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study, The Lancet Oncology, Volume 13, Issue 11, November 2012, Pages 1096-1104, ISSN 1470-2045, 10.1016/S1470-2045(12)70436-9. link to article